New Treatment Saves Children With Terminal Brain Cancer
Summary
This episode explores TAAT, a new immunotherapy showing promise for treating deadly pediatric brain tumors by training immune cells to attack cancer without genetic modification. Host James Woodford and Alice Klein discuss early trial results where some terminal patients achieved long-term remission. They also cover future trials combining TAAT with ultrasound and personalized antigen targeting, alongside Australia’s Zero program using genetic sequencing to identify specific cancer drivers.
Topics discussed
Sponsor message from Accenture
Introduction: The challenge of pediatric brain tumors
How TAAT immunotherapy works
Why previous immunotherapies failed for brain tumors
The TAAT process: Training immune cells in the lab
Clinical trial participants and their grim prognosis
Trial results: Remarkable recoveries and safety profile
Expert perspective on trial limitations and hope
Future trials: Ultrasound and personalized antigen targeting
Hope for higher survival rates in future treatments
Why brain tumors are common in children
Australia's Xero program and genetic sequencing success
Episode conclusion and sign-off
Sponsor message from Verizon
Listen ad-free on Castria